Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Obesity
Interventions: Intervention Control, Counselling, Contrave, Contrave and Counseling; Behavioral · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Scottsbluff, Nebraska

Conditions: Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions: Sustained Care, Standard Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Cigarette Smoking
Interventions: Extended Care Management, Standard Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 75 Years
Enrollment: 589 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolism, Pharmacokinetics
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression
Interventions: sertraline, bupropion; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 542
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more

Conditions: Obesity
Interventions: Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Upton, New York

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Bupropion XL; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking, Homeless Persons
Interventions: Bupropion, Nicotine replacement therapy, Contingency Management; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Bupropion XL 300; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions: AXS-05 (dextromethorphan-bupropion); Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 21
States / cities: Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more

Conditions: Treatment Resistant Depression
Interventions: Discontinuation of serotonergic antidepressants, Continuation of serotonergic medications; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Smoking
Interventions: Bupropion HCl ER, Placebo; Drug
Lead sponsor: Mark Eisenberg; Other
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 13
States / cities: Pueblo, Colorado • Lewiston, Maine • Bay City, Michigan + 9 more

Conditions: Binge Eating Disorder, Obesity
Interventions: bupropion, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Abdominal Wall Hernia
Interventions: Preoperative Weight Management Program; Other
Lead sponsor: Benjamin T. Miller; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Smoking Cessation, Smoking, Tobacco, Smoking (Tobacco) Addiction, Cessation, Tobacco, Cigarette Smoking
Interventions: Bupropion Hydrochloride; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Smoking Cessation
Interventions: ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer, ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer, Data Driven Feedback reports; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression, Side Effects, Sexual Dysfunction, Apathy
Interventions: Wellbutrin XL; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline; Drug
Lead sponsor: Centre for Addiction and Mental Health; Other
Eligibility: 60 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • St Louis, Missouri • New York, New York

Conditions: Depressive Disorder
Interventions: WellbutrinXL, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alcohol Drinking, Depression, Smoking Cessation, Attention Deficit Disorder
Interventions: Trial Withdrawn 1, Trial Withdrawn 2; Other
Lead sponsor: Tufts University; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

Smoking Interventions for Hospital Patients

Maintenance Treatment for Abstinent Smokers

Pharmacogenetics of Bupropion Metabolism

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Dynamic Measures of Neurochemistry in Mood Disorders

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Connectivity Affecting the Antidepressant REsponse Study

Contingency Management for Smoking Cessation in Homeless Smokers

Clinical Study of Generic and Brand Bupropion in Depression

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Antidepressant Discontinuation in Treatment Resistant Depression

Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial

Craving, Binge Eating and Obesity

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

High Dose Bupropion for Smoking Cessation - Pilot Study

Electronic Health Record-Enabled Evidence-Based Smoking Cessation Quality Improvement Implementation Program

Wellbutrin XL Effects on SSRIs Induced Changes

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression